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Abstract
Background Due to the high risk of recurrence of non-muscle invasive bladder cancer, all patients undergo regular cysto-
scopic surveillance for early detection. As cystoscopy is invasive, costly and increases the burden of the disease considerably, 
there is significant ongoing research and development into non-invasive urinary biomarker substitutes. This study aims to 
assess the level of sensitivity required before patients accept a new urinary biomarker.
Methods We studied the preferences for a hypothetical diagnostic urinary biomarker and compared this to usual care (cys-
toscopy) at different levels of sensitivity among 437 patients with bladder cancer (354 men and 83 women) from the UK 
Bladder Cancer Prognosis Programme. A standard gamble approach was used to estimate the minimally acceptable sensitivity 
(MAS) of the new biomarker. Additionally, non-parametric statistical analyses were performed to investigate the association 
between surveillance preference and various patient characteristics.
Results Almost half of patients (183, 43%) would not replace cystoscopy with a urinary biomarker unless it was 100% sensi-
tive. The median MAS was 99.9999%, and nearly 85% of patients demanded a sensitivity of at least 99% before preferring 
a urinary biomarker test over cystoscopy. These results were consistent across all patient characteristics and demographic 
categories.
Conclusions Our results indicate that patients demand urinary biomarkers as sensitive as cystoscopy before they would be 
willing to forego cystoscopy for bladder cancer surveillance.
Keywords Non-muscle-invasive bladder cancer · Non-invasive biomarkers · Sensitivity and specificity · Standard gamble
Introduction
Bladder cancer is the ninth most common malignancy 
worldwide, with a rising global incidence [1]. The majority 
of patients (75–80%) present with non-muscle-invasive dis-
ease (NMIBC) [2, 3]. Although not immediately life threat-
ening in the majority of cases, recurrence and progression 
of NMIBC remain significant issues [4, 5], with up to 55% 
of patients experiencing recurrence within 5 years of diag-
nosis [6]. Current guidelines recommend long-term surveil-
lance except for low-risk NMIBC after 12 months [5]. With 
a global prevalence that can be estimated at over 2,000,000, 
at any one time, there will be a very considerable number of 
patients requiring such surveillance [1].
Surveillance typically comprises outpatient flexible cys-
toscopy and urine cytology [5, 7]. For patients with low-risk 
NMIBC, European Association of Urology (EAU) guide-
lines recommend follow-up cystoscopy and urine cytology 
at 3 months and 12 months after tumour resection (TURBT), 
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and then annually for the next 5 years. Patients with high-
risk NMIBC undergo more intensive surveillance—every 
3 months for the first 2 years, every 6 months until 5 years, 
and yearly thereafter, most likely for the rest of their lives 
[5]. If recurrence is detected, then the tumour is resected 
and surveillance will re-commence from the beginning. It 
has been estimated that each cystoscopy and urine cytology 
episode costs £533 [8]; consequently, bladder cancer is the 
most expensive cancer to treat on a per patient basis from 
diagnosis to death, with the majority of expense attributable 
to NMIBC [9, 10].
Cystoscopy itself significantly increases the burden of 
disease—it is an invasive procedure that causes pain and 
discomfort in about one-third of patients [11]. In contrast, 
previous studies have shown that the only burden attribut-
able to a non-invasive test (such as a urinary biomarker) is 
the waiting time for the test result [11]. For these reasons, a 
number of diagnostic urinary biomarkers have been devel-
oped by academia and industry in an attempt to create less 
burdensome and less costly NMIBC surveillance regimens.
Urine cytology is widely used as an adjunct to cystos-
copy. It has high sensitivity for detecting high-grade disease 
( ± 80%), but poor sensitivity for low-grade disease ( ± 30%) 
[12, 13]; in addition, diagnostic accuracy depends upon a 
number of confounding factors, such as the quality of the 
sample and the level of expertise of the cytopathologist [14].
More recently, other types of diagnostic urinary biomark-
ers have been developed, including soluble urine markers 
and exfoliated cell markers, as well as multigene urinary 
DNA-based tests [15, 16]; some are commercially available 
and US FDA approved [17]. As summarised by Soria et al. 
in 2018, such biomarkers have moderate to good sensitiv-
ity, and multigene panels can reach sensitivity levels of over 
90% in patients with high-grade tumours [17]. Biomarker-
driven surveillance might become a realistic possibility 
if, or when, they reach a sufficient and consistent level of 
sensitivity [18], bearing in mind that cystoscopy itself is 
operator dependent with the sensitivity and specificity of 
conventional white light cystoscopy estimated to be up to 
85% and 87%, respectively [9, 19].
However, what is less clear is what level of sensitivity is 
acceptable to patients undergoing surveillance for NMIBC, 
such that they would be willing to switch from cystoscopy, 
which in practitioners’ eyes is perceived as the golden stand-
ard. Only two studies have previously published on this 
subject. Vriesema et al., in a utility analysis on 85 patients 
(70 men and 15 women) undergoing bladder cancer surveil-
lance in The Netherlands, found that 68% of their patients 
had a minimally acceptable sensitivity (MAS) of over 99% 
[20]. The more cystoscopies a patient had undergone, the 
higher was their MAS, suggesting that the acceptability of 
cystoscopy increases with patients’ familiarity with and/or 
confidence in the procedure. In a similar utility analysis on 
200 patients (119 men and 81 women), Yossepowitch et al. 
reported that 70% of 200 patients recruited in the United 
States had a MAS over 99%, and only 24.5% would accept 
a MAS lower than 95% [21].
The objective of this study was to assess the level of 
biomarker acceptability in a NMIBC population naïve to 
conventional cystoscopic surveillance, as well as assessing 
factors that may affect levels of acceptability, such as socio-
demographics and social support.
Materials and methods
This study is part of the West Midlands Bladder Cancer 
Prognosis Programme BCPP), which is an ongoing mul-
ticentre patient cohort study in the West Midlands region 
of the UK [22]. Adult patients (age > 18 years) presenting 
with symptoms suspicious for bladder cancer haematuria in 
over 80% [23] in the 10 participating urology centres within 
the region were enrolled on the basis of cystoscopic find-
ings suggestive of bladder cancer. Those who had a previous 
diagnosis of cancer of the urethra, bladder, ureter or renal 
pelvis within the last decade, HIV infection, or any other 
condition that might interfere with the safety of the par-
ticipant were excluded. The study received ethical approval 
as part of BCPP (reference: 06/MRE04/65), and written 
informed consent was obtained from all participants.
At the time of diagnosis, trained research nurses con-
ducted semi-structured face-to-face interviews to collect 
information on socio-demographics, health-related lifestyle 
(lifetime smoking history, passive smoking, use of hair dye), 
medical and drug history, dietary intake, social support and 
HRQoL. HRQoL was assessed with the European Organisa-
tion for Research and Treatment of Cancer EORTC) Quality 
of Life Questionnaire, the QLQ-C30 [24]. Social support 
was assessed with the Duke-UNC Functional Social Sup-
port Questionnaire FSSQ) [25]. The FSSQ is an eight-item 
instrument, scored on a 1–5 scale, which measures the 
strength of a person’s social support network. Both the QLQ-
C30 and the FSSQ were converted to a scale ranging from 
0 to 100, with 0 as the lowest quality of life or lowest level 
of perceived social support and 100 as the highest. Only the 
overall HRQoL scale from the QLQ-C30 was used, as we 
hypothesised that the burden of the cystoscopy would affect 
overall HRQoL rather than any specific HRQOL domain or 
symptom. Participants were followed up at approximately 
3 months post-baseline measurement with a similar ques-
tionnaire. During this follow-up, changes in health-related 
lifestyle and HRQoL were assessed.
We employed a utility-based patient preference 
questionnaire to assess the patient’s preference for cys-
toscopy versus a hypothetical urinary biomarker test. 
Using a ‘standard gamble’ procedure, we posed a series 
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of questions in which the patient was asked to choose 
between two surveillance tests, a cystoscopy or a hypo-
thetical urinary biomarker test [26]. The sensitivity of 
the hypothetical urinary biomarkers started at 100% and 
decreased in each subsequent question. The definition of 
sensitivity was explained to the patient as the number of 
tumours missed by the biomarker out of a thousand. The 
MAS was defined as the lowest value of accuracy at which 
the biomarker was favoured over the cystoscopy.
Due to the non-normal distribution of the MAS data, we 
used non-parametric statistical analyses to investigate the 
association between surveillance preference and various 
patient characteristics. This included the Mann–Whitney/
Wilcoxon rank-sum test and Spearman’s rank correlation 
coefficient. In addition, we conducted exploratory logistic 
regression analyses in which we dichotomised the outcome 
variable (MAS) to identify differences between patients 
that were willing to sacrifice any sensitivity ( < 100%) and 
those that were not (100% only). Stratified analyses were 
used to identify any possible effect modification. Lastly, 
sensitivity analyses were conducted where patients with 
an MAS of “0%” and an MAS of “100%” were excluded. 
All analyses were performed with Stata/MP version 12. A 
p value of < 0.05 was considered statistically significant.
Results
During the recruitment period (2005–2011), 1536 par-
ticipants were enrolled. Of these 1536 patients, 326 were 
excluded because they did not have primary bladder cancer, 
another 23 were lost to follow-up, and 514 were excluded 
as they did not complete the first questionnaire, leaving 673 
patients potentially available for assessment see Fig. 1. Of 
these 673 patients, 437 (65%) responded to the standard 
gamble section and were included in the analyses. These 
437 participants were slightly different to the 236 who did 
not complete the standard gamble with regards to gender 
(p = 0.05) and age (p = 0.04), whereby the non-respond-
ers were older and more likely to be female (25% in non-
responders vs. 19% in responders, p = 0.05).
Of the 437 study participants, 354 were male and 83 were 
female, the mean age was 69 years old, with a minimum 
of 33 and maximum of 90 years. 309 patients (73%) had a 
partner with whom they were married or living together. The 
Fig. 1  Flow chart depicting 
patient recruitment in the Blad-
der Cancer Prognosis Pro-
gramme (BCPP) cohort study 
and inclusion for the current 
study
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median overall HRQoL as measured by the QLQ-C30 was 
75 interquartile range (IQR: 58—83), and the median social 
support was 100 (IQR: 88—100) Table 1.
187 patients (43%) would not change from a cystoscopy 
to a biomarker unless the biomarker had a sensitivity of 
100%. In fact, the median value of MAS was 99.9999%, 
and nearly 85% of patients indicated that they would require 
a sensitivity of at least 99% before preferring a urinary bio-
marker test over cystoscopy.
We did not observe any statistically significant asso-
ciations between the MAS and age (p = 0.092), HRQoL 
(p = 0.161), or social support score (p = 0.566) Table 2. The 
distribution of MAS scores across the categorical variables 
of gender (p = 0.127), marital status (p = 0.374) and level 
of educational attainment (p = 0.060) did not differ, and no 
effect modification was found Table 3.
Discussion
Our results indicate that the large majority of patients 
recently diagnosed with bladder cancer demand a very high 
level of sensitivity before they would be willing to accept 
urinary biomarkers as an alternative to cystoscopy for peri-
odic surveillance. Based on the conclusions of Vriesema 
et al. (2000) [20], we expected that our population of cys-
toscopy naïve patients would indicate a lower MAS and 
therefore have a larger spread of responses. However, we 
observed the opposite. When comparing the results of previ-
ous studies to our results, it is clear that patients choose test 
certainty over test burden.
In all three studies [20, 21], more than 65% of the patients 
indicated that they would require an MAS of over 99% and 
approximately 90% of patients would require an MAS of 
over 90% Table 4. None of the existing biomarkers are able 
to consistently achieve this level of sensitivity.
The high percentage of patients that would not prefer a 
MAS with sensitivity below 100% may reflect less than a 
full understanding of the concept of sensitivity, and also the 
fact that these patients were presented with a hypothetical 
situation. However, based on qualitative feedback from the 
research nurses who administered the standard gamble, it 
is our impression that many patients were “terrified” of the 
possibility of missing a tumour.
Table 1  Patient characteristics of all patients included in the analysis
Non-muscle-invasive bladder cancer (NMIBC)
Muscle-invasive Bladder Cancer (MIBC)
Age
 Mean (SD) 68.8 (10.4)
 Range 33–90
Sex
 Male (%) 348 (81%)
 Female (%) 82 (19%)
Marital status
 With partner (%) 305 (73%)
 Without partner (%) 111 (27%)
General health
 Median (IQR) 75 (58.3–83.3)
 Range 8–100
Social support
 Median (IQR) 100 (87.5–100)
 Range 0–100
Stage
 NMIBC
  pTis (%) 6 (1%)
  pTa (%) 245 (57%)
  pT1 (%) 238 (32%)
MIBC
  pT2 (%) 37 (9%)
Table 2  Results from Spearman 
rank correlation analysis 
between MAS, age, general 
health and social support score
Age
 Spearman’s rho − 0.081
 p value    0.092
General health
 Spearman’s rho    0.087
 p value    0.161
Social support score
 Spearman’s rho    0.034
 p value    0.566
Table 3  Results from Mann–Whitney U and Kruskal–Wallis test 
comparing rank sums of MAS between sex, marital status and NVQ 
levels
Variable n per category Rank sum
Sex
 Male 348 76,010
 Female 82 19,693
 p value of Mann–Whitney U test 0.127
Marital status
 With partner (%) 305 66,297
 Without partner (%) 111 22,957
 p value of Mann–Whitney U test 0.374
National Vocational Qualifications (NVQ)
 Level 1 43 5124
 Level 2 57 7896
 Level 3 81 10,513
 Level 4 33 4513
 Level 5 37 3579
p value of Kruskal–Wallis test 0.060
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It is important to place these findings in the context of 
conventional white light cystoscopy as the “gold standard” 
for the diagnosis of NMIBC. However, new optical tech-
nologies such as photodynamic diagnosis and narrow band 
imaging [27] have shown that the sensitivity of conventional 
white light cystoscopy itself is much less than 100%, and 
that recurrent tumours are missed in up to 41% of patients 
[28]. Most patients in this study will have been unaware of 
the shortcomings of conventional white light cystoscopy and 
thus believed and readily accepted the 100% sensitivity that 
we used as a cystoscopy benchmark against which biomark-
ers were to be compared.
We also hypothesised that patients who perceive the bur-
den of the cystoscopy to be high would be more inclined to 
choose a lower MAS. In a similar manner, patients with a 
low health-related quality of life (HRQOL) would find the 
burden of the cystoscopy to be higher and thus choose a 
lower MAS. In addition, we hypothesised patients with more 
social support would be willing to take more risk and thus 
have a lower MAS. Education was taken into account as we 
hypothesised that patients with a higher education would 
better understand the risk associated with cystoscopy and 
the benefit of having a urinary biomarker, even if it comes 
at the cost of sensitivity. We demonstrated that there was no 
significant association between MAS and National Voca-
tional Qualifications level, although the highest levels (level 
four & five) seemed to report lower MAS values more often 
(p = 0.060).
Even though there was a moderate to high response rate 
(65%) in a patient population, we found little evidence of 
any significant difference between the patients who did and 
did not take part in the survey. Nevertheless, we cannot rule 
out the possibility that the MAS of the larger population 
might be somewhat different from that of our study sample. 
Furthermore, with bladder-preservation strategies being 
used more frequently for the treatment of muscle-invasive 
bladder cancer MIBC) with curative intent [29], one should 
recognise that this group of patients also require long-term 
cystoscopic surveillance; their opinions and MAS may dif-
fer from those of NMIBC patients. With only a relatively 
small sample of MIBC patients in this study (n = 37, 9%), 
we have been unable to make this comparison adjusting for 
any patient characteristics, although it should be noted that 
the lowest reported MAS was 90% in MIBC patients, while 
10.5% (n = 43) of NMIBC patients reported a MAS of 90% 
or lower.
Two previous studies by Vriesema et al. and Yossepow-
itch et al. reported incongruent findings of associations 
between age and MAS, and gender and MAS; neither study 
was able to replicate the findings of the other [20, 21]. Our 
study did not replicate findings of either of the two previous 
studies. This lack of association across the studies between 
the various potential risk factors and MAS might be due to 
the small variance in MAS. Additionally, it might be pos-
sible that we did not find an association between age and 
MAS, because mostly older patients did not complete the 
questionnaire.
Moreover, patients were newly diagnosed when they filled 
in the questionnaire, increasing the observer-expectancy 
effect as the subject is in a temporary, vulnerable mind state 
and the research nurse might show empathy with the patient 
while a neutral stance is expected. Also, patients were pre-
sented with cystoscopy as a 100% accurate test as their ref-
erence, while the actual accuracy of cystoscopy is lower, 
especially in diagnosing low-grade disease. Future studies 
should consider rephrasing questions about MAS to make 
clear that the reference test is not by definition 100% accu-
rate. Both caveats could increase the risk of inappropriately 
interpreting results.
Our results suggest that the bladder cancer biomarker 
research and development community, both commercial 
and academic, needs to aim for test sensitivity equal to or 
better than cystoscopy before such tests can be implemented 
into NMIBC surveillance regimens. This is unlikely to be 
achievable with the current generation of urinary biomarkers 
but may be achievable in the near future with urinary DNA-
based approaches [16]. Future research should also focus 
on costs of such non-invasive biomarkers, for example, by 
investigating how much patients are willing to pay for each 
increment in diagnostic accuracy. Cystoscopy is unlikely 
to be replaced today, but tomorrow’s urinary biomarkers 
may allow the frequency of cystoscopic surveillance to be 
reduced.
In conclusion, our study results indicate that patients 
demand more sensitive urinary biomarkers than are currently 
available, thus patients choose certainty over burden.
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